<p> Indian medical startup CORE Diagnostics has entered into a new partnership with leading US-based molecular diagnostics company Paradigm to bring to India the latter’s advanced cancer profiling service, PCDx (Paradigm Cancer Diagnostic), which helps in detailed personalising of each cancer patient’s course of treatment.<br /><br /></p>.<p>Paradigm, the molecular information and Next Generation Sequencing (NSG) corporation specialising in providing tumor analysis for patients with cancer to help find the optimal treatments, has signed a distribution agreement with CORE Diagnostics to facilitate patient access to PCDx, in India. <br /><br />PCDx is a comprehensive clinical-grade NGS-based test that is designed to provide physicians and patients with a more targeted, personalised approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a tumors DNA, RNA and Protein. The test interrogates the most relevant genomic targets at over 5,000x average depth of coverage with 72 therapeutic associations, the release added.</p>
<p> Indian medical startup CORE Diagnostics has entered into a new partnership with leading US-based molecular diagnostics company Paradigm to bring to India the latter’s advanced cancer profiling service, PCDx (Paradigm Cancer Diagnostic), which helps in detailed personalising of each cancer patient’s course of treatment.<br /><br /></p>.<p>Paradigm, the molecular information and Next Generation Sequencing (NSG) corporation specialising in providing tumor analysis for patients with cancer to help find the optimal treatments, has signed a distribution agreement with CORE Diagnostics to facilitate patient access to PCDx, in India. <br /><br />PCDx is a comprehensive clinical-grade NGS-based test that is designed to provide physicians and patients with a more targeted, personalised approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a tumors DNA, RNA and Protein. The test interrogates the most relevant genomic targets at over 5,000x average depth of coverage with 72 therapeutic associations, the release added.</p>
